Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Cancer

Ver/ abrir
Use este enlace para citar
http://hdl.handle.net/2183/33770
A non ser que se indique outra cousa, a licenza do ítem descríbese como Atribución 4.0 Internacional
Coleccións
- Investigación (FIC) [1634]
Metadatos
Mostrar o rexistro completo do ítemTítulo
Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal CancerAutor(es)
Data
2023-09-16Cita bibliográfica
Bao-Caamano, A., Costa-Fraga, N., Cayrefourcq, L. et al. Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer. Sci Rep 13, 15401 (2023). https://doi.org/10.1038/s41598-023-42037-w
Resumo
[Abstract] Circulating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients.
Versión do editor
Dereitos
Atribución 4.0 Internacional
ISSN
2045-2322